Azenta Q3 FY26 adjusted EPS climbs to $0.16; revenue rises 12% to $161 million

Azenta reported Q3 fiscal 2026 revenue of $161 million, up 12% year over year; adjusted EPS was $0.16.

Adjusted EBITDA margin fell 0.6 percentage points to 11.4%; free cash flow was negative $5 million.

Results reflected strength in recurring revenue businesses including Biorepositories and C&I, while Sanger sequencing continued to decline year over year.

Cash and marketable securities totaled $529 million as of June 30, 2026; there was no debt outstanding.

For Q4 fiscal 2026, organic revenue is expected to decline low single-digit; adjusted EBITDA is guided to $20 million-$23 million.